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Abstract
Yeasts are largely used as bioreactors for vaccine production. Usually, antigens are produced in yeast then purified and
mixed with adjuvants before immunization. However, the purification costs and the safety concerns recently raised by the
use of new adjuvants argue for alternative strategies. To this end, the use of whole yeast as both production and delivery
system appears attractive. Here, we evaluated Pichia pastoris yeast as an alternative vaccine production and delivery system
for the circumsporozoite protein (CS) of Plasmodium, the etiologic agent of malaria. The CS protein from Plasmodium
berghei (Pb) was selected given the availability of the stringent C57Bl/6 mouse model of infection by Pb sporozoites,
allowing the evaluation of vaccine efficacy in vivo. PbCS was multimerized by fusion to the measles virus (MV) nucleoprotein
(N) known to auto-assemble in yeast in large-size ribonucleoprotein rods (RNPs). Expressed in P. pastoris, the N-PbCS protein
generated highly multimeric and heterogenic RNPs bearing PbCS on their surface. Electron microscopy and
immunofluorescence analyses revealed the shape of these RNPs and their localization in peripheral cytoplasmic inclusions.
Subcutaneous immunization of C57Bl/6 mice with heat-inactivated whole P. pastoris expressing N-PbCS RNPs provided
significant reduction of parasitemia after intradermal challenge with a high dose of parasites. Thus, in the absence of
accessory adjuvants, a very low amount of PbCS expressed in whole yeast significantly decreased clinical damages
associated with Pb infection in a highly stringent challenge model, providing a proof of concept of the intrinsic adjuvancy of
this vaccine strategy. In addition to PbCS multimerization, the N protein contributed by itself to parasitemia delay and long-
term mice survival. In the future, mixtures of whole recombinant yeasts expressing relevant Plasmodium antigens would
provide a multivalent formulation applicable for antigen combination screening and possibly for large-scale production,
distribution and delivery of a malaria vaccine in developing countries.
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Introduction
Antigen delivery is a major issue in the success of vaccines.
Although only a few adjuvants are licensed [1], a large array of
chemical-based new adjuvants or immunostimulants for vaccine
antigens are currently developed [2]. However, several concerns
about the safety of using chemicals in association with vaccines are
raised [3,4,5,6,7]. Therefore, alternative delivery strategies need to
be developed. Among them, the use of attenuated [8] or
inactivated [9,10,11] yeast is emerging. Yeast-based vaccines elicit
both humoral and cell-mediated immune responses in the absence
of adjuvants [9,10,11,12]. Heat-killed yeasts have been shown to
protect mice against systemic aspergillosis and coccidioidomycosis
[13], or to provide sterile protection to chicken towards infectious
bursal disease [14]. Recombinant yeasts are currently developed as
vaccine candidates against HBV and HCV in humans [15] or
leukemia [16]. Whole yeasts activate dendritic cells (DCs) and are
efficiently taken up through fungipods or phagocytic synapses on
DCs [17,18]. Both mannose and Dectin-1 receptors mediate the
interaction between human DCs and the most biotechnologically
relevant yeasts: Saccharomyces cerevisiae (S. cerevisiae) and Pichia pastoris
(P.pastoris) [19]. DCs can distinguish direct fungal contacts from
soluble fungal-derived components through the Dectin-1 pattern-
recognition receptor [18]. Thus, activated DCs become potent
presenting-cells for antigens expressed in recombinant yeast, and
efficiently deliver antigens into both MHC class I and class II
pathways. Hence, yeast-DC interplay provides a strong adjuvant
effect on antigen immunogenicity [9,10,11,12].
Multimerization of monomeric antigens was also largely
demonstrated to amplify their immunogenicity through increased
uptake by DCs [20,21,22,23]. Thus, combining the antigen
multimerization with expression in whole yeast would be even
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more advantageous. Several multimeric proteins, generally from
viral origin, have been used as delivery systems [24,25,26,27]. The
nucleoprotein (N) of measles virus (MV), which composes the viral
helical nucleocapsid [28,29], has the capacity to auto-assemble
around any RNA molecule in the cytoplasm of cells in which this
protein is expressed (mammalian [30], bacterial [31] or yeast [32])
with a ratio of 1 N molecule to 6 ribonucleotides. This gives rise to
helical, highly stable, and multimeric ribonucleoprotein rods
(RNPs) similar in shape and diameter to RNPs present in MV viral
particles [33]. The expression of MV-N protein in P. pastoris
GS115 yeast strain induces the formation of high amounts of these
RNPs visible in the cytoplasm by electron microscopy [32]. Thus,
whole recombinant yeast expressing MV-N appears as a promising
delivery system for multimerizing vaccine antigens.
Currently tested whole yeast-based vaccine candidates are based
on S. cerevisiae yeast. In 2009 the entire genome of P. pastoris yeast
(GS115 strain) was sequenced [34]. This encouraged the
development of P. pastoris as bioreactor in vaccinology. Indeed,
P. pastoris offers many advantages compared to S. cerevisiae, such as
the stringent control of protein production through a strong
inducible promoter and the reduced length of the oligosaccharide
chains eventually added post-translationally to transgenic proteins.
Moreover, terminal alpha-1,3 glycan linkages on glycosylated
proteins, which are responsible for hyper-antigenicity effects of
antigens produced in S. cerevisiae [35], are not formed in P. pastoris.
To evaluate a new vaccine platform based on recombinant
whole yeast as antigen delivery vector for multimerized antigens,
we used a malaria animal model. Despite major research efforts,
an efficient malaria vaccine is still not available [36]. Hence, it is
worthwhile to investigate new approaches. Malaria is caused by
the multiplication of Plasmodium parasites in the blood after
injection in the skin by a mosquito. The parasite form in the skin,
called sporozoite, invades hepatocytes to develop into red blood
cell (RBC) infecting forms, during the pre-erythrocytic phase of
infection [37]. The Plasmodium sporozoite is covered with the
monomeric circumsporozoite protein (CS), the leading vaccine
candidate against the pre-erythrocytic stage of Plasmodium [38,39].
Antibodies to CS [40,41,42], as well as specific CD8+ T cells
[42,43,44], are known to protect against sporozoite challenge in
animal models, primarily rodents. In humans, RTS,S - the most
advanced malaria vaccine candidate based on the CS antigen -
provides 30–56% protection [45]. In RTS,S, CS multimerization
is achieved by its association to hepatitis B virus-like particles.
Here, CS multimerization is obtained by fusing the CS from
Plasmodium berghei (Pb) ANKA strain (a rodent-infective species) to
the N protein from MV. We generated recombinant P. pastoris
yeast expressing N or PbCS alone, or N-PbCS RNPs, and
characterized the size, shape and cellular localization of these RNP
structures. Heat-inactivated recombinant yeasts were used to
immunize C57Bl/6 mice, the most susceptible laboratory mice to
Pb sporozoite infection [46]. In this model, most animals die
during the first 10 days post infection presenting symptoms of
experimental cerebral malaria, or later as a consequence of
extreme red blood cell infection [47]. Following subcutaneous
immunization with whole yeast expressing N-PbCS RNPs then
intradermal challenge with Pb sporozoites, the onset of blood
infection was significantly delayed, and animal survival was
prolonged. The profile of anti-PbCS IgG antibodies reflected
unbiased contributions of both Th1 and Th2 immune responses.
Results
Expression of Measles virus Nucleoprotein in Pichia
pastoris
The nucleotide sequence encoding the nucleoprotein (N) of
measles virus vaccine (MV) Schwarz strain [48] was optimized for
expression in P. pastoris and cloned into the pPIC3.5K plasmid
under the control of the methanol-inducible AOX1 promoter.
Three strains of P. pastoris (the commonly used GS115 and KM71,
as well as SMD1168, which is deficient in proteinase A activity)
were transformed with the recombinant plasmid and 10 positive
clones per strain were amplified. A first kinetic study of N
expression was performed by western blot analysis of yeast lysates.
The optimal time point for N expression was found to be 54 hours
(h) after methanol induction for the three P. pastoris strains. The
best N-expressing clone for each strain was then selected by
western blot analysis of yeast lysates collected 54 h after induction.
These clones showed the highest expression of full-length
undegraded N of comparable weights (Figure 1). The N expression
was further characterized in the GS115, KM71, and SMD1168
best clones by Bradford analysis and quantitative western blot.
The N protein was expressed at the predicted apparent molecular
weight with no visible degradation or processing. The amount of N
protein expressed was around 1 mg per yeast unit (YU). In the
GS115 and KM71 strains, N production accounted for as much as
24% of total soluble proteins (TSP), while this was only 14% in the
SMD1168 strain (Table 1). The expression levels in GS115 and
KM71 were in the same range as previously shown for these
strains [32].
Expression of N-PbCS in SMD1168 Pichia pastoris
To test the possibility of using MV-N-based RNPs as carrier to
multimerize heterologous antigens in malaria vaccine prototypes,
we fused the circumsporozoite (CS) antigen [49] from Pb (ANKA
strain) to the C-terminus of MV-N through a linker of 7 amino
acids (Figure 2A; Figure S1; [50]). The choice of using Pb opens
access to the mouse animal model to evaluate the immunogenicity
and efficacy of the vaccine prototype by vaccination and parasite
challenge [46,47]. GS115, KM71 and SMD1168 P. pastoris strains
were transformed by pPIC3.5K bearing the N-PbCS-encoding
gene under the control of the AOX1 methanol-inducible
promoter. Induction of N-PbCS in GS115 and KM71 strains
resulted in the rapid degradation of the fusion protein (data not
shown), while the full-length fusion protein was correctly produced
Figure 1. Expression of N protein in GS115, KM71 and
SMD1168 P. pastoris strains. Concentrations of Geneticin in selection
plates for the specific clones, and clone numbers, are indicated. Yeast
lysates were diluted 1/600 before loading on western blot.
doi:10.1371/journal.pone.0086658.g001
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in SMD1168 strain (Figure 2B). The maximum expression of N-
PbCS was obtained at 54 h after induction. In the best N-PbCS
expressing clone selected by qualitative and quantitative western
blot, the expression level of fusion protein (12 ng/YU) was 73
times lower than N alone (871 ng/YU) in the same strain (Table 1;
Figure 2C). Thus, full length N-PbCS fusion protein could only be
expressed in SMD1168 P. pastoris and at a nearly 2-log lower level
than the N protein alone. In order to obtain control yeast
expressing the monomeric form of the Plasmodium antigen, an
SMD1168 clone producing PbCS alone was generated and
selected as previously described. PbCS yeast showed a comparable
expression level of the antigen alone (16 ng/YU) to that of the N-
PbCS yeast (12 ng/YU). The replication kinetics of recombinant
SMD1168 yeasts expressing N, PbCS or N-PbCS were strictly
comparable in all tested culture media (YPD, BMG and BMM),
and no macroscopic phenotype difference was observed between
recombinant and wild type SMD1168 yeasts.
Production of High Molecular Weight N-based
Ribonucleoproteins in Pichia pastoris
The MV-N nucleoprotein has the capacity to auto-assemble
around RNA in the cytoplasm of mammalian, bacterial or yeast
cells [30,31,32]. To assess whether N and N-PbCS were assembled
into high-molecular weight RNPs in SMD1168 P. pastoris, yeast
lysates were ultracentrifuged on 30% sucrose and the presence of
N and PbCS proteins was quantified in fractions and pellets
(Figure 3). Although N multimerization may impact the affinity of
RNPs of different size for anti-N antibodies used for quantifica-
tion, a comparison of N amounts can be performed among
fractions at similar levels in N and N-PbCS samples. For both
recombinant yeasts, the profile of N and N-PbCS distribution on
sucrose showed the presence of monomeric or oligomeric N in the
upper fractions, multimeric forms in the middle fractions and
highly multimeric RNPs in the pellets. Notably, we estimated by
calculation routine (see Materials and Methods) that RNPs present
in the pellets were heavier than 36,502 kDa, assembling more than
628 N molecules. The 2-log difference in read out between the
two recombinant yeasts relates to the 2-log difference in N
expression level between N and N-PbCS yeasts (871 ng/YU
versus 12 ng/YU).
Remarkably, in N-PbCS recombinant yeast, N was predomi-
nantly found in the pellet. Quantitative western blot analysis of N-
PbCS pellets demonstrated that RNPs were mainly constituted of
N (70–80%) and that full length N-PbCS protein represented 10–
20% of total N. In addition, recombinant RNPs contained 10% of
degraded N-PbCS proteins (data not shown). The imbalanced
profile of N-PbCS yeast may be due to RNP pull down by
interaction of PbCS antigen with subcellular elements or
alternatively to RNPs stabilization by N-PbCS fusion resulting in
highly multimeric RNPs. Heterologous antigen expression did not
modify yeast RNA and TSP patterns as compared to wild type
yeasts (Figure S2). Theses profiles were maintained independently
of yeast amounts loaded on sucrose (data not shown).
To look for the structure of RNPs, yeast lysates were observed
by electron microscopy (EM). In the N recombinant SMD1168
yeast, we found numerous RNPs with herringbone shape of 20–
22 nm diameter and variable rod length of 30 to 200 nm
(Figure 4A). This finding was similar to that previously described
in recombinant P. pastoris GS115 strain [32] and in mammalian
cells infected by MV [29]. In the N-PbCS sample, RNPs appeared
less rigid than N-only RNPs with length spanning from 30 to
70 nm. Most N-PbCS RNPs were detected in microenvironments
where discrete rings were visible next to rod-like structures
(Figure 4B). Because of the lower expression level of N-PbCS as
compared to N, the N-PbCS clarified lysate was submitted to two
ultracentrifugation rounds to concentrate N-PbCS structures,
while N sample was not. This explains the differences observed
in average rod length in both samples, as previously observed for
N RNPs in yeast [32]. Moreover, after the first round of
ultracentrifugation we selected the fractions containing RNPs of
around 333 N molecules, which represented the major population
as compared to shorter or longer RNP structures present in the
other ultracentrifugation fractions or pellet. This assumption was
made taking into account that 1 N molecule associates with
6 RNA ribonucleotides [29], and that eukaryotic mRNAs have an
average size of 2 kb [51]. RNP selection was then performed on
the basis of a sedimentation calculation routine (see Methods). The
presence of lighter and heavier N-PbCS RNPs in lysate as well as
of N-PbCS fusion protein in selected RNPs was put in evidence by
anti-PbCS/anti-N sandwich ELISA on all 1 ml fractions taken
from the top to the bottom of tubes from both ultracentrifugation
rounds (data not shown).
Immunofluorescence analysis of N or N-PbCS recombinant
SMD1168 yeasts showed that RNPs localized in large and
compact cytoplasmic inclusions, as previously observed for N
alone in GS115 P. pastoris [32], and that N inclusions co-localized
with PbCS in N-PbCS yeasts (Figure 5).
Heat-inactivation of Pichia pastoris
The development of P. pastoris for whole recombinant yeast
vaccine, as an alternative to S. cerevisiae, needs to set up a protocol
of heat-inactivation ensuring the death of vegetative yeast cells
before their use. A recombinant S. cerevisiae previously tested in
Phase IIb trial was heat-inactivated at 56uC for 1 h [15]. As this
protocol only partially inactivated P. pastoris GS115, we evaluated
a series of inactivation temperatures and time of treatment to
achieve complete impairment of yeast growth. Survival of P.
pastoris GS115, KM71 and SMD1168 yeasts after different heat-
treatments was analyzed by culture both on plates and in liquid
medium for 7 days at 30uC. The total loss of reproductive capacity
was associated to the lack of metabolic activities, as assessed by
methylene blue viability test. Complete growth impairment for the
three strains was obtained following heat-inactivation at 58–60uC
for 45–60 minutes (Figure S3). For the next experiments, we used
60uC for 45 minutes.
Evaluation of the Immunogenicity and Efficacy of Whole
Recombinant N-PbCS SMD1168 Yeast Vaccine in the
Plasmodium berghei - C57Bl/6 Mouse Model
To evaluate the immunogenicity and efficacy of whole
recombinant SMD1168 P. pastoris expressing MV-N-based RNPs
as carrier of PbCS antigen, we used the C56Bl/6 mouse model of
Table 1. Amount of N protein expressed in P. pastoris GS115,
KM71 and SMD1168 strains. One YU corresponds to 107 yeast
cells.
P. pastoris strain
GS115 KM71 SMD1168
N protein amount per YU (mg) 1.25 1.14 0.87
Total soluble protein (TSP)
per YU (mg)
5.11 4.63 5.98
N protein/TSP (%) 24 24 14
doi:10.1371/journal.pone.0086658.t001
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Pb infection, a highly stringent animal model for severe rodent
malaria [46]. Immunizations were performed by five subcutaneous
injections (once every week) of 30 YU heat-inactivated SMD1168
P. pastoris in the absence of accessory adjuvant (Figure 6). Two
separate experiments were independently performed with five
groups of mice in each (6 and 8 mice per group, respectively). The
first group was inoculated with yeast expressing N-PbCS (360 ng
of N-PbCS corresponding to 230 ng of N and 130 ng of PbCS
antigens); the second group with yeast expressing PbCS only
(130 ng of PbCS antigen); the third group with yeast expressing N
only (230 ng of N); the fourth group with wild type (WT) yeast. In
groups two and three, recombinant yeast was diluted with wild
type SMD1168 yeast to adjust the amounts of PbCS or N with
respect to the N-PbCS group. A last group was kept unvaccinated,
but housed in parallel (naive). Bleedings were performed every
week during immunization and just before challenge (day 42). All
groups of mice were challenged at day 43 with 6,000 GFP+ Pb
sporozoites, then parasitemia and mouse survival rate were
monitored. GFP+ Pb sporozoites were used to facilitate parasitemia
determination by flow cytometry (these modified Pb sporozoites
have similar growth and infectivity rates than wild type parasites
[52]).
The results obtained in the two immunization experiments were
comparable, showing the robustness of outputs despite two
independent sporozoites and recombinant yeasts preparations.
Therefore, to improve statistical robustness, we pooled the results
from both experiments into a single analysis (Figure 7 and
Figure 8).
All mice immunized with N-PbCS yeast raised anti-PbCS
antibodies after the third immunization whose level still increased
in half of the animals after the last injection (Figure 7A). Median
IgG titer reached 36104 at day 42 when immunization was
completed (Figure 7B). By contrast, mice immunized with yeast
expressing PbCS only remained negative all over the follow up
(data not shown). Retrieving anti-PbCS antibody response despite
a very low antigen dose (130 ng PbCS per injection) in the N-
PbCS group as compared to the PbCS group demonstrates the
self-adjuvant capacity of this vaccine platform, notably the positive
impact of antigen multimerization by N-based RNPs.
Figure 2. Expression of N-PbCS in P. pastoris. (A) Schematic representation of N-PbCS fusion protein. MV-N (dark grey) is composed of a core
domain in N-terminal and a unstructured tail domain in C-terminal [69]. The GAAGAGA linker is in black. PbCS (light grey) corresponds the central
repeat region flanked by major portions of the N-terminal and C-terminal domains of the protein [39]. Amino acids numbering are given according to
N from the MV Schwarz vaccine strain and PbCS from the Pb ANKA strain. For sequence details, see Figure S1. (B) Quantitative western blot analysis of
SMD1168 expressing N-PbCS or (C) N. In (B) and (C), yeast lysates were diluted as indicated, the MV-N protein was used as a standard with increasing
concentrations and western blots were probed with an anti-N antibody.
doi:10.1371/journal.pone.0086658.g002
Pichia pastoris as Malaria Vaccine Vector
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As IgG subclasses mediate different immune effector functions
depending on their structures [53], we determined the IgG
subclass responses to PbCS in N-PbCS immunized mice before
challenge (Figure 7B). There was no Th1 or Th2 polarization of
the humoral immune response since the IgG1 response was
statistically comparable to IgG2b, and the relevant difference
between IgG1 and IgG2a (p,0.05) was compensated in the Th2/
Th1 bias by the IgG2b response (Mann-Whitney nonparametric
test). Remarkably, the detection of significant IgG1 and IgG2a/b
humoral responses underlines the elicitation of both Th1 and Th2
cytokine environments after vaccination with the whole recombi-
nant N-PbCS yeast in the absence of accessory adjuvants.
Anti-N IgG antibodies became detectable after the third
injection in mice immunized with N or N-PbCS yeasts and
reached highest titers at day 42. The anti-N response at day 42
(Figure 7C) was statistically comparable in both N and N-PbCS
Figure 3. ELISA quantification of N or PbCS proteins in ultracentrifugation (U) fractions and pellets of SMD1168 lysates expressing
N alone at 871 ng/YU (A) or N-PbCS at 12 ng/YU (B). Yeast cultures, lysates and ultracentrifugations were performed in duplicate (3 U and 4 U
for N expressing yeast, and 5 U and 6 U for N-PbCS yeast). Values correspond to optical densities at OD450 nm (taking OD620 nm as reference)
multiplied by sample dilutions. SB: suspension buffer.
doi:10.1371/journal.pone.0086658.g003
Figure 4. Electron microscopy analysis of yeast lysates from SMD1168 P. pastoris expressing N (A) or N-PbCS (B). Scale bars are
indicated. Black arrows highlight RNP rod and ring structures.
doi:10.1371/journal.pone.0086658.g004
Pichia pastoris as Malaria Vaccine Vector
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immunized groups, excluding immune interference between N
and PbCS antigens in anti-N humoral response. The anti-N
antibody response was more variable among the animals than the
anti-PbCS response, with even three mice from both groups that
remained negative. This was not due to administration or vaccine
uptake problems, as the two negative mice from the N-PbCS
group (Figure 7C) had high anti-PbCS responses (Figure 7A and
Figure 7B). Comparison between the anti-N and anti-PbCS
antibody titers in the N-PbCS group shows a trend towards inverse
correlation between these titers, the majority of mice having
higher anti-PbCS than anti-N antibody titers (10 out of 14 mice,
i.e. 71%; Figure 7D). This may indicate immunodominance of
PbCS over measles N antigen. Lastly, all immunized mice showed
anti-P. pastoris antibody responses towards whole (Figure 7E) or
lysed P. pastoris (Figure 7F), and naive mice did not present anti-P.
pastoris cross reacting antibody responses (data not shown).
Two weeks after the last immunization, all mice were
challenged with 6,000 GFP+ Pb sporozoites and the parasitemia
(proportion of parasite-containing RBCs) was determined at early
time points during parasite exponential growth (Figure 8A). From
day 3 to 6 after challenge, the parasitemia was comparable in the
N, PbCS and WT groups where iRBC reduction was not
statistically different from the naive control group, however the
N group showed a difference from the naive group at day 5
(p,0.05; Figure 8B). In contrast, parasitemia was significantly
reduced in the N-PbCS group (notably around 4–fold at day 5
post-challenge; p,0.005 at days 4 and 5, and p,0.0005 at day 6;
Figure 8B). The parasitemia reduction observed in animals
immunized with N-PbCS as compared to animals immunized
with PbCS correlates with the induction of PbCS antibodies and
confirms that multimerization of the antigen on RNPs made the
difference. We observed that mice dying early (day 7–14)
presented clinical signs of experimental cerebral malaria, whereas
after day 20 mice died as a consequence of hyper-parasitemia (up
to 35–55% of iRBCs/RBCs at day 20, and 60–70% at day 25).
The parasitemia at day 5 and the day of death showed a significant
inverse correlation (Spearman test; p,0.005): a low parasitemia
(0–0.2%) preferentially resulted in a late death, while a higher
parasitemia (.0.2%) resulted in a more rapid death associated
with experimental cerebral malaria (Figure 8C). Immunization
with N-PbCS yeasts increased survival since 10 out of 14 mice of
this group were still alive at day 22 after challenge, while most
mice from PbCS, WT and naive groups died around day 11
(Figure 8D). Nevertheless, a similar benefit on survival at later
times was also observed in the group of mice immunized with
yeasts expressing N only, thus indicating that N may contribute to
the survival advantage observed in the N-PbCS group. Notably, in
the N-PbCS group, mice with the highest anti-PbCS IgG levels
Figure 5. Immunofluorescence analysis of N or N-PbCS expression in yeasts (N staining in green, PbCS staining in red and nuclei in
blue). Each image is the maximal intensity projection of three consecutive focal planes spaced 0.5 mm apart.
doi:10.1371/journal.pone.0086658.g005
Figure 6. Schematic representation of the immunization protocol. Immunization and challenge schedule is given in days (d) and bleeding
time points in weeks.
doi:10.1371/journal.pone.0086658.g006
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Figure 7. Humoral responses elicited in mice after immunization. (A) Kinetics of anti-PbCS IgG responses in mice immunized with N-PbCS
yeasts. OD450 nm are expressed in log10 scale. Black arrows indicate immunization schedule. (B) Isotyping of humoral IgG responses at day 42 in mice
Pichia pastoris as Malaria Vaccine Vector
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had the most prolonged survival, although antibody titers were not
predictive of early or late animal death outcome (Mann-Whitney
nonparametric test).
Discussion
Vaccine manufacturers largely use yeast as bioreactor for
producing high amounts of low cost vaccines, the best example
immunized with N-PbCS. The bars correspond to median values per group. Asterisks (*) indicate significant median differences (p,0.05; Mann-
Whitney nonparametric test). (C) Anti-N IgG titers in mice serums collected at day 42 after immunization with WT yeast or yeasts expressing N, PbCS
or N-PbCS. Median values were compared by the Wicoxon Two Sample Test (p = 0.4558). (D) Antibody titers of N-PbCS mice are compared (see
panels B and C). The lines associate titers from the same mouse. (E) Anti-P. pastoris IgG responses towards whole yeast. (F) Anti-P. pastoris IgG
responses towards lysed yeast. The bars in (E) and (F) correspond to mean values per group. Hash sign (#) indicates anti-N antibody-negative mice
from the N-PbCS group (see panel C).
doi:10.1371/journal.pone.0086658.g007
Figure 8. Experimental challenge of immunized mice. (A) Mean and standard deviations log10 values of parasitemia in mice immunized by N-
PbCS, PbCS, N or WT yeast, and in non-immunized mice following infection with 6,000 GFP+ Pb sporozoites. Blood parasitemia is expressed in log10
scale as the percentage of infected red blood cells (iRBCs) out of total RBCs along the first 7 days follow up. Asterisks (*) indicate the significance level
of the Mann-Whitney nonparametric test: two symbols correspond to p,0.005 and three to p,0.0005. (B) Parasitemia at day 5 post-challenge. Bars
correspond to medians. Asterisks (*) indicate significant median differences (one symbol for p,0.05 and two for p,0.005; Mann-Whitney
nonparametric test). (C) Inverse correlation between the day of death (x axis) and the percentage of iRBCs per total RBCs (y axis; arithmetic scale) per
mouse. The cause of death is given in the upper part of the graph. (D) Survival curves of immunized mice after challenge with 6,000 GFP+ Pb
sporozoites.
doi:10.1371/journal.pone.0086658.g008
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being the anti-hepatitis B (HBV) vaccine (ENGERIX-BH). This
vaccine is based on the HBV small surface antigen (HBsAg) and is
manufactured in S. cerevisiae yeast. Like in all yeast-based vaccines
currently on the market, ENGERIX-BH HBsAg is produced and
purified from yeasts. Attempts to validate S. cerevisiae as both an
antigen bioreactor and a delivery system are currently ongoing in
preclinical and clinical trials. An HCV therapeutic vaccine (GI-
5005) was tested in Phase IIb, and an HBV therapeutic vaccine
(GI-13000) is undergoing preclinical studies (http://www.
globeimmune.com/). These vaccine candidates are based on S.
cerevisiae, as most whole yeast-based vaccine candidates [13,16].
Nevertheless, P. pastoris is an interesting alternative in the
development of whole yeast vaccines, since this species introduces
less post-translational modifications on heterologous antigens than
S. cerevisiae [35]. Moreover, unlike S. cerevisiae, P. pastoris is
particularly suitable for the fermentative growth and has the
ability to reach very high cell densities during fermentation, which
may improve overall protein yields [54].
With this in mind, we set up a vaccine production and delivery
system based on the heterologous expression of measles virus
nucleoprotein (MV-N) in P. pastoris. We show here that the
spontaneous assembly of this protein in P. pastoris provides a mean
to multimerize heterologous antigens. As a proof of concept, we
fused to MV-N the circumsporozoite protein (CS) from Plamodium
berghei (Pb), the etiologic agent of rodent malaria [46]. The CS
protein is present on the surface of Plasmodium sporozoites (10 pg
per sporozoite [55]) when they are inoculated into the skin of the
host [37,49,56]. Antibodies [40,41,42] and cellular responses
[42,43,44] elicited against CS both seem to confer protection, and
the most advanced malaria vaccine candidate (RTS,S) is based on
this antigen [57]. Full results from the phase III trial of RTS,S are
expected in 2015. Current estimates of vaccine efficacy in the 12
months following three doses were 30–56%, depending on age
group and endpoint [58]. Nevertheless, recent phase IIb analysis
showed that RTS,S efficacy is inversely correlated with transmis-
sion intensity, dropping to zero in a three-year perspective [59].
This is in strong support for developing second-generation malaria
vaccine strategies. In the present work, fusion of PbCS to MV-N
resulted in antigen multimerization into ribonucleoprotein rod-like
structures localized in the cytoplasm of recombinant yeasts.
Injected subcutaneously in the absence of accessory adjuvants
and at low antigen dose (130 ng PbCS per injection), the N-PbCS
P. pastoris induced a significant delay in the emergence of
parasitemia as well as prolonged survival of recipient C57Bl/6
mice following a stringent challenge consisting in the intradermal
injection of a high number (6,000) of infectious Pb sporozoites.
Comparing both the induction of specific antibodies to PbCS
antigen and the outcome of experimental challenge among N,
PbCS and N-PbCS immunization groups indicates that multi-
merization of PbCS on RNPs was necessary to significantly
decrease early parasitemia and to increase mice survival. However,
we also observed that measles virus N carrier protein contributes
by itself, together with Plasmodium antigen multimerization, to
parasitemia delay and to long-term mice survival. This might be
due to innate immune responses or to the activation of CD8 or
CD4 T-cells, although we could not analyze those responses as no
T-cell responses or specific T-epitopes have been described in the
C56Bl/6 mouse model of Pb infection [60]. Anti-PbCS IgG
responses reflected unbiased contribution of Th1 and Th2
immune responses, indicating broad elicitation of the immune
system in the absence of accessory adjuvants. Future studies will be
dedicated to clarify the specific role in adjuvancy of N-based RNPs
and of heat-inactivated whole P. pastoris yeast, as well as the
possible role of T cell responses.
Nevertheless, this initial study shows that expression of the CS
antigen in P. pastoris needs to be improved. It is assumed that the
CS proteins from Pb (infecting mice) and P. falciparum (infecting
humans) share conformational and function properties, although
they present around 60% divergent amino acids sequences [39].
To determine whether CS expression in P. pastoris depends on
specific protein sequence, we generated MV-N fusion proteins
with equivalent CS domains from P. falciparum (strain 3D7; PfCS)
and from PbCS. Full length N-PfCS (92.73 kDa) was produced in
P. pastoris GS115 and KM71 at 97 ng/YU (data not shown), while
N-PbCS (91.32 kDa) was not produced in GS115 or KM71
strains, and only at lower yield in SMD1168 strain (12 ng/YU).
These data indicate that primary amino acid sequence determines
the efficiency of N-CS fusion protein expression in P. pastoris. Yeast
proteases are major actors in foreign protein degradation. As only
general knowledge is available on protease targets essentially from
S. cerevisiae, further studies are required for improving the yield of
production of MV-N based fusion protein in P. pastoris. Neverthe-
less, the better production yield observed for PfCS as compared to
PbCS in P. pastoris is favorable for developing a human vaccine
relying on this strategy.
The administration regimen is an important issue for whole
inactivated yeast. In this study, we show that three injections at
one-week interval were necessary to elicit detectable anti-CS
antibody response in most mice. In preliminary experiments we
observed that three injections at two-week interval (d0, d14, d28)
did not induce anti-CS antibodies or parasitemia delay (data not
shown). Whether this is due to the low expression level of N-PbCS
in SMD1168 strain (12 ng/YU) or to the intrinsic feature of whole
recombinant P. pastoris needs to be addressed. Increasing antigen
production yield by further selection of expressing clones is
obviously required. However, frequent boosts might be needed to
elicit robust long-term immune responses. Multiple doses with
whole recombinant yeast were tested as administration protocols
for therapeutic vaccination with myostatin [61], K-Ras oncopro-
tein [62] or HCV NS3 and Core (GI-5005; [15]). Notably in this
last study, up to 13 weekly doses of whole recombinant yeast
showed no yeast neutralization in mouse or toxicity in rabbit, and
cellular immune responses increased in parallel with injection
frequency [15]. However, for logistic and economic reasons, no
more than three vaccine administrations can be scheduled for
preventive immunization of infants living in areas of malaria
endemicity. Future improvement of whole recombinant yeast such
as increasing the antigen expression level, testing alternative
administration pathways or yeast formulation, has to be addressed
to enhance vaccine efficiency with fewer administrations.
Many immunogenic antigens from Plasmodium parasites were
described. Although correlates of protection against malaria in
humans are still elusive, the combination of Plasmodium antigens
from both the asexual and sexual phases of infection in a single
multi-stage formulation might make it possible to induce sterile
immunity in humans and prevent parasite transmission. Current
vaccine platforms towards malaria provide either monovalent
(subunit or DNA/viral vector vaccine candidates), or multivalent
formulations (whole organism vaccine candidates: i.e. genetically
attenuated parasites, radiation-attenuated sporozoites, and live-
parasite immunization under antimalarial therapy) [63]. The
monovalent vaccine platforms, even in heterologous immunization
protocols, result in poorly diversified antigen combinations and
show at best partial protection towards infection. By providing all
antigens from Plasmodium at specific replication stages, same
vaccine protocols from the multivalent vaccine strategies are
successful in eliciting sterile immunity. However, whole organism
vaccine candidates are still limited by hardly solvable logistic
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problems for large-scale production, distribution and delivery in
developing countries.
Mixtures of whole recombinant yeast clones, each expressing
relevant Plasmodium antigens for the asexual and sexual stages,
provide the means to deliver multi-antigen cocktails in a vaccine
formulation which can guarantee low costs of production and be
independent from cold chain constraints for vaccine delivery in
developing countries.
Materials and Methods
Recombinant Yeast Production and Characterization
The N and the PbCS nucleotide sequences were synthesized
and optimized for expression in P. pastoris (GeneScript), and cloned
within EcoRI and NotI restriction sites into the pPIC3.5K plasmid
(Invitrogen) for yeast expression under the control of the
methanol-inducible AOX1 promoter. In the N-PbCS fusion
protein, a linker of 7 amino acids (GAAGAGA) was inserted
between the N and PbCS genes. GS115, KM71 and SMD1168
yeast strains were transformed by electroporation and plated on
RDB plates (histidine-deficient medium) for the first round of
clone selection (HIS+ clones). Screening of clones with multiple
inserts was performed on YPD-Geneticin plates at a final
antibiotic concentration of 0.25 to 4.0 mg/ml (G8168-100,
Sigma-Aldrich). Details on yeast culture mediums and plates are
given in Invitrogen User Manuals for P. pastoris.
Kinetics and levels of N, PbCS and N-PbCS protein expression
were monitored upon methanol induction. Yeast clones were
cultured in BMG medium over weekend, then transferred to the
BMM medium and protein production was induced and
maintained by adding 0.5% methanol to cultures every 24 h.
Before lysis, yeast cells were quantified by spectrophotometer
analysis at OD600 nm. Collected culture samples were lysed every
24 h using acid-washed glass beads (425–600 mm; G8772 Sigma-
Aldrich) and Breaking Buffer (Invitrogen). Following mechanic
lysis, yeast extracts were centrifuged at 134 g for 10 minutes, and
then supernatants clarified by centrifugation at 371 g for 15
minutes. Western blot (WB) was performed in denaturing
conditions on 4–12% Bis-Tris polyacrylamide gels with XT
MOPS buffer (Criterion 345-0123, Bio-Rad) using the Color Plus
Prestained Protein Ladder (7–200 kDa; P7711 BioLabs), nitrocel-
lulose membranes (HybondTM-C Extra RPN303E; Amersham
Biosciences), and as primary antibodies the anti-N clones 25 or
120 (a gift from Mathias Faure and Chantal Rabourdin-Combe;
[64]) or the anti-PbCS antibody obtained through the MR4 as
part of the BEI Resources Repository, NIAID, NIH: Mus musculus
(B cell); Mus musculus (myeloma) 3D11, MRA-100, deposited by V
Nussenzweig. Primary antibodies were at 1/1,000 dilution over
night at 4uC and the secondary HRP-conjugated sheep anti-mouse
IgG antibody (GE Healthcare UK Limited, NA931V) at 1/5,000
dilution for 1h30 at room temperature. In quantitative WB,
selected clones were induced in BMM and cultures stopped at
54 h. Yeast was quantified (yeast unit; YU) by spectophotometer
analysis (OD600 nm) and lysed. Lysed samples were diluted as
indicated, and loaded on gel in parallel to the N standard protein
(GenScript) at predefined quantities (10 to 20 ng). The anti-N
clone 25 was used as primary antibody. N and N-PbCS band
intensities were quantified by the Luminescent Image Analyzer
LAS-1000 plus (FUJIFILM) and reported on the N standard
curve. Total soluble proteins (TSP) in lysates were measured by
Bio-Rad Bradford Assay.
Size of MV RNPs Expressed in Pichia pastoris
After methanol induction for 54 h, yeast cultures were stopped
on ice and samples (4,325 YU) were lysed and resuspended in
2 ml suspension buffer (SB: TrisHCl 25 mM pH 7.5, NaCl
50 mM, EDTA 2 mM in UltraPureTM DNase/RNase-Free
Distilled Water) supplemented with anti-protease cocktail (Roche)
and rRNasin RNase Inhibitor (Promega). The 2 ml samples were
loaded on 9 ml 20% sucrose cushion in SB and centrifuged in
SW41 Ti rotor for 1 h at 36,000 rpm at 4uC. Fractions of 1 ml
were collected using the MasterflexH L/SH compact pump
sampling machine (Cole-Parmer). Pellets were resuspended in
1 ml SB. Each aliquot including the pellet was analyzed for total
soluble proteins (TSP), total RNA and N or N-PbCS protein
concentrations by Bio-Rad Bradford Assay, NanoDrop 1000
Spectrophotometer, and anti-N or anti-PbCS sandwich ELISA.
PCR analysis on lysed yeast cultures before and after centrifuga-
tion at 134 g and on clarified lysates was performed by a classical
protocol using Taq DNA polymerase from Invitrogen and the 59
AOX1 (Invitrogen) and the 39 NOPT-INTER (59-
TTGTTCAGTCTGACCAGTCTC) primers resulting in a 437-
nucleotide band on recombinant yeast genome. Anti-N and anti-
PbCS sandwich ELISA were performed by coating in sodium
carbonate buffer (pH 9.6) 0.5 mg/ml of the mouse anti-N
(MAB8906 Millipore) or 1/2,000 dilution of the MR4-100 anti-
PbCS monoclonal antibody, and using the anti-N rabbit
polyclonal IgG antibody (ABIN346975 Antibodies-Online
GMBH) at 1/10,000 in 1xPBS as primary antibody, and the
anti-rabbit IgG-HRP (NA934V Amersham Biosciences) at 1/
7,000 dilution in 1xPBS as secondary antibody. Anti-N ELISA
positive controls were SMD1168 expressing N protein, lysed and
diluted at 1/200, 1/400 and 1/800 in 1xPBS. Anti-PbCS ELISA
positive control was N-PbCS SMD1168 lysate (1/200) before
loading on ultracentrifugation tube. ELISA plates were read with
the EnSpire 2300 Multilabel Reader (Perkin Elmer) at OD450 nm,
using OD620 nm as reference wavelength. Fractions and pellets
collected from ultracentrifugation tubes with no yeast (SB only
loaded on 20% sucrose) showed negative background of reagents
in all the performed tests (ELISA, NanoDrop and Bradford).
A sedimentation calculation routine (developed by Dr Raynal,
Institut Pasteur, and provided on demand) was set up in Microsoft
Excel using classical Svedberg equations to predict the distance
(cm) at which the protein of interest migrates from the upper
surface of solutions in ultracentrifugation tubes. The calculation
takes into account: (i) the protein mass and structure to estimate
the vbar and Sw20 sedimentation parameters; (ii) ultracentrifuga-
tion tube characteristics and rotor diameter; (iii) sucrose percent-
age and volume for each solution phase; (iv) ultracentrifugation
time; and (vi) rotation speed (rpm).
Electron Microscopy
SMD1168 yeasts expressing N or N-PbCS were lysed and
clarified as described above. EM was directly performed on N
clarified lysate, while the N-PbCS clarified lysate was concentrated
by ultracentrifugation on 20–60% sucrose gradient for 1 h30 at
32,000 rpm (SW32 Ti). The fractions at the interphase were
collected, and further ultracentrifuged on 30% sucrose cushion for
4 h at 32,000 rpm (SW32 Ti) to collect the pellet. Samples were
spotted on glow discharged carbon coated grids (EMS, USA) and
negatively stained with NanoW (Nanoprobes, USA) [65]. Samples
were then observed at 120 kV with a Philips/FEI CM 12
transmission electron microscope. Images were recorded using a
KeenView camera (OSIS, Germany) and ITEM software (OSIS,
Germany). RNP length and diameter were estimated as the
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average measures of 50 particles counted manually. Measurement
standard deviation was 5%.
Immunofluorescence Analysis
After induction of protein expression, 50 YU per sample were
fixed by 3.7% formaldehyde. Cell wall was digested by zymolyase
(Sigma-Aldrich: L2524-50KU), and cells were fixed again by
methanol/acetone and attached to microscope slides as described
[66]. Cells were labeled with a rabbit polyclonal anti-MV-N
(Covalab pab0035; 1/500 dilution) or MRA-100 mouse anti-
PbCS monoclonal antibodies (1/1,000 dilution), then Alexa 488
goat anti-rabbit IgG (H+L) (Invitrogen A-11008; 1/500 dilution)
or CY3-AffinityPure F(ab’)2 Frag goat anti-mouse IgG (Jackson
ImmunoReasearch 115-166-072; 1/1,000 dilution) as secondary
antibodies. Bright field and fluorescence images were acquired on
a motorized inverted wide field fluorescence microscope. The
system was controlled by the AxioVision software (Release 4.8.2.0,
Zeiss) and was composed of a motorized inverted microscope
(AxioObserver Z.1, Zeiss) equipped with a halogen illuminator
(HAL100, Zeiss), a metal halide illuminator (HXP120, Zeiss) and a
CCD camera (AxioCam MR, Zeiss). DAPI, Alexa Fluor and Cy3
were detected with specific filter sets. Stacks of 6 focal planes
spaced 0.5 mm apart were acquired with a 100x oil objective (EC
Plan-Neofluar 100x/1,30 Oil Iris, Zeiss). Images were then
processed with the ImageJ software [67].
Heat-inactivation of Pichia pastoris
GS115, KM71 or SMD1168 yeast strains were cultured in YPD
medium at 30uC and 250 YU were pelleted at 134 g for 10
minutes, medium was carefully removed and the yeast pellet
treated at indicated temperatures and time points in a water bath.
Heat-inactivation was stopped by transferring samples on ice. One
YU of each sample was then plated on YPD/agar and cultured for
7 days at 30uC. The viability test was performed by adding 20 ml
of methylene blue solution (Sigma-Aldrich; 0.05 mmol21 in PBS
pH 7.2) to the same volume of yeast cell suspensions and dead cell
counting was performed under optical microscopy. For immuni-
zations, whole SMD1168 wild type yeast or yeast expressing N,
PbCS or N-PbCS (54 h cultures) were heat-inactivated at 60uC for
45 minutes and resuspended in 1xPBS at 30 YU/50 ml.
Mice Immunization, Flow Cytometry, Survival Rate and
ELISA Analyses
Six weeks old C56Bl/6 females were housed and included in
experimental protocol groups following the European Directive Nu
2010/63/UE. The experimental protocol was submitted and
approved by the Ethic Comity Ile-de-France – Paris 1 (Nu 2012-
0009). All the experimenters had a regulatory authorization for
animal handling delivered by the accredited French authorities
and accepted by Institut Pasteur Animal Facility. All efforts were
made to minimize animal suffering and to reduce the number of
animals used. Mice were injected subcutaneously (50 ml) in
correspondence of inguinal lymph nodes and bleedings (100 ml)
were performed 3 days before the first immunization (day minus 3)
or 6 h before next immunizations. Following the last bleeding
(d42), mice were challenged at d43 with 6,000 sporozoites per
mouse (1 ml, injected intradermally in the posterior footpad).
Sporozoites were freshly collected by salivary gland dissection from
Anopheles stephensi infected with Pb ANKA strain expressing the
GFP (GFP+) under the control of the hsp70 promoter [52]. After
challenge, mice were monitored daily during two weeks for clinical
signs of neurological disorder, then twice a day up to day 29 for
the animals that recovered from initial symptoms. To determine
the clinical benefits of vaccination and avoid arbitrary outcomes,
mice were not euthanized before day 15. Beyond day 15, surviving
mice did not show any predictive symptom till sudden death,
despite hyper-parasitemia. In the present study, most of the mice
that survived beyond day 15 did recover from clinical symptoms
and in these mice we did observe early signs of cerebral malaria.
Signs of cerebral malaria were motor troubles, ruffled fur and
sometimes convulsions. If mice showing these signs had been
euthanized before day 15, or had received any treatment, the
outcome of the experiment (possibility to recover from cerebral
malaria) would have been arbitrarily changed. No significant
weight change was observed. Parasitemia level was not correlated
to the day of death. Identified moribund mice were euthanized by
C02 treatment in an appropriate chamber.
Blood samples (2 ml) were collected from day 3 to 7, diluted in
600 ml 1xPBS and analyzed in plates by Fluorescence Activated
Cell Sorting (FACS; MacsQuant, Miltenyi Biotec). Doublets and
clusters of red blood cells (RBCs) were excluded from counts.
Single GFP+ RBCs (infected RBC, iRBCs) among total RBCs
were estimated and data analyzed by the MACSQuantifyTM
Software.
For IgG quantification in blood, sera from bleedings were
separated from blood samples by Capiject T-MG Capillary Blood
collection System (Terumo Medical Corporation) and stored at
220uC untill ELISA tests. The anti-PbCS IgG ELISA was
performed by coating wells with 50 mg of recombinant PbCS
protein produced at the Recombinant Protein and Antibodies
Production Core Facility of the Institut Pasteur by J. Bellalou and
V. Bondet, using the BioPod F800 microfermentor battery (Fogale
Nanotech) [68]. The anti-PbCS monoclonal antibody from the
MR4-100 reagent was used for positive controls at 1/4,000 and 1/
10,000 dilutions. Anti-N IgG ELISA was performed by coating in
wells 50 mg of .70% pure recombinant N protein (Genscript) and
using the monoclonal mouse anti-N primary antibody (MAB8906,
Millipore) at 1/5,000 and 1/20,000 dilutions in 1xPBS, Tween
0.05% and BSA 0.5% for positive controls. Anti-P. pastoris IgG
ELISA was performed by coating 25 YU of whole or lysed wild
type P. pastoris per well in sodium carbonate buffer (pH 9.6). Yeast
was previously cultured, inactivated and lysed as described.
Saturation of wells by whole or lysed yeast was determined by
using an anti-P. pastoris rabbit polyclonal antibody (BP2240, Acris
Antibodies) at 1/200 dilution and an anti-rabbit IgG-HRP
(NA934V Amersham Biosciences) at 1/10,000 dilution. Serial
dilutions of serum samples (1/100, 1/1,000, 1/10,000 and 1/
100,000 for anti-PbCS and anti-N; 1/300 and 1/1,000 for anti-P.
pastoris) were incubated on plates then HRP-conjugated sheep
anti-mouse IgG secondary antibody (NA931V, GE Healthcare
UK Limited) was used at 1/5,000 dilution in PBS together with
3,39,5,59-Tetramethylbenzidine substrate (TMB; Sigma-Aldrich)
for detection. ELISA development was stopped after 5 minutes
with 2N H2SO4 and plates were read at OD450 nm, using
OD620 nm as reference wavelength. In ELISA determination of
IgG isotypes, the polyclonal goat anti-mouse ads-HRP IgG (1030-
05: dilution 1/8,000), IgG1 (1070-05; dilution 1/4,000), IgG2a
(1080-05; dilution 1/4,000) and IgG2b (1090-05; dilution 1/4,000)
from Southern Biotech were used as secondary antibodies. Sera
were diluted by two folds from 1/50 to a maximum of 1/614,400.
Titers were determined as the inverse of the highest sample
dilution for which the OD450 nm signal was greater than the cut off
(the mean optical density plus 3 times the standard deviation of
pre-immune control sera from mice under study). Mann-Whitney
nonparametric and Spearman tests were performed using
GraphPad Prism version 5.0 b for Mac OS X (GraphPad
Software, San Diego California USA, www.graphpad.com), and
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the Wilcoxon Two Sample test (http://www.fon.hum.uva.nl/
Service/Statistics/Wilcoxon_Test.html).
Supporting Information
Figure S1 Optimized nucleotide sequence of the N (A)
and PbCS (B) proteins for expression in GS115, KM71
and SMD1168 P. pastoris strains. The nucleotide sequence
of the linker between N and PbCS is given in the box (B); (C)
Kyte-Doolitle hydropathy profile (DNA Strider1.4f18) of N-PbCS:
negative values correspond to hydrophilic amino acid motifs.
(TIF)
Figure S2 Total RNA (A, B and C) and Total Soluble
Protein (TSP; D, E and F) in fractions (Fr) and pellets
from ultracentrifuged samples (U) in duplicate. (A and D)
SMD1168 P. pastoris transformed with pPIC3.5K without insert;
(B and E) SMD1168 P. pastoris expressing N; (C and F) SMD1168
P. pastoris expressing N-PbCS. SB: suspension buffer. PCR analysis
targeting the gene insert demonstrated the absence of genomic
DNA (of nucleus origin) in samples analyzed by NanoDrop for
total RNA content.
(TIF)
Figure S3 Heat-inactivation of P. pastoris GS115, KM71
and SMD1168. The hyphen (-) corresponds to incomplete
inactivation and ‘‘n.v.’’ to not-viable yeast. In the figure: test of P.
pastoris reproductive activity on YPD plates following heat-
inactivation. Each spot corresponds to 1 YU (56107 cells), out
of 250 YU samples, loaded on a YPD/agar plate and cultured
over 7 days at 30uC. GS115 heat-treated samples are numbered
on horizontal lines from 1 to 8, KM71 from 9 to 16 and SMD1168
from 17 to 24. (A) GS115, (B) KM71, and (C) (SMD1168) samples
were not submitted to heat-treatment, while all the other spots
were submitted to 58uC for 45 minutes (1, 2, 9, 10, 17, 18) or 60
minutes (3, 4, 11, 12, 19, 20), and to 60uC for 45 minutes (5, 6, 13,
14, 21, 22) or 60 minutes (7, 8, 15, 16, 23, 24). Untreated samples
actively grew (A, B and C), while all heat-inactivated samples (from
1 to 24) were completely arrested in their reproductive activity
(visible spots correspond to 1 YU loaded on plates).
(TIF)
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